Sign In
Buy TECH
$56.26
+0.650 (+1.17%)
At Close: Jun 23, 2026
CMB.TECH results general meetings
10:46am, Thursday, 22'nd May 2025
Antwerp, May 22, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMBT”, “CMB.TECH” or “the Company”) announces that today the General Meeting of Shareholders has app
CMB.TECH announces Q1 2025 results
01:09am, Wednesday, 21'st May 2025
CMB.TECH ANNOUNCES Q1 2025 RESULTS 1 BILLION USD CONTRACT BACKLOG ADDED ANTWERP, Belgium, 21 May 2025 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT & Euronext: CMBT) re
ST. PAUL, Minn. , May 14, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady announced today three G-Rex Grants that
Bio-Techne to Showcase Next-Generation Solutions for Gene and Cell Therapy at American Society of Gene & Cell Therapy 2025
07:00am, Monday, 12'th May 2025
MINNEAPOLIS , May 12, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its latest spatial biology and cell and gene therapy workflow solutions at the America
CMB.TECH announces Q1 2025 results on 21/05/25
02:35am, Monday, 12'th May 2025
Antwerp, May 12, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMBT”, “CMB.TECH” or “the Company”) will release its first quarter 2025 earnings prior to market openi
CMB.TECH CEO Speaks On Shifting Investor Focus From Asset Values To Sustainable Earnings Power
02:23pm, Friday, 09'th May 2025
Capital Link's Trending News Webinar Series featured this week a discussion with Mr. Alexander Saverys, CEO of CMB.TECH CMBT, who shared his views on the company's diversified business model, plans fo
Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing
09:30am, Thursday, 08'th May 2025
Kytopen and Bio-Techne announce partnership on an integrated cellular engineering workflow to expedite cell therapy manufacturing. The TcBuster™ system offers a fast and scalable method to integrate
Bio-Techne to Present at the BofA Securities 2025 Health Care Conference
07:00am, Thursday, 08'th May 2025
MINNEAPOLIS , May 8, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the BofA Securities 2025 Heal
Bio-Techne Q3 Earnings & Revenues Top Estimates, Stock Up in Premarket
11:05am, Wednesday, 07'th May 2025
TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment in third-quarter fiscal 2025.
Bio-Techne Corporation (TECH) Q3 2025 Earnings Call Transcript
10:38am, Wednesday, 07'th May 2025
Bio-Techne Corporation (NASDAQ:TECH ) Q3 2025 Earnings Conference Call May 7, 2025 9:00 AM ET Company Participants David Clair - Vice President-Investor Relations Kim Kelderman - President & Chief Exe
Techne (TECH) Reports Q3 Earnings: What Key Metrics Have to Say
10:36am, Wednesday, 07'th May 2025
Although the revenue and EPS for Techne (TECH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street e
Is the Options Market Predicting a Spike in BioTechne Stock?
09:35am, Wednesday, 07'th May 2025
Investors need to pay close attention to TECH stock based on the movements in the options market lately.
Techne (TECH) Q3 Earnings and Revenues Beat Estimates
08:40am, Wednesday, 07'th May 2025
Techne (TECH) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.48 per share a year ago.
Bio-Techne exceeds profit expectations, announces new share buyback plan
08:18am, Wednesday, 07'th May 2025
Bio-Techne on Wednesday beat Wall Street estimates for third-quarter profit, driven by growth in its unit that provides proteins, antibodies and other products for research and said it is launching a
BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS
06:30am, Wednesday, 07'th May 2025
MINNEAPOLIS , May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2025. Third Quarter FY2025 Highlights Third
